Compare ASUR & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASUR | ELTX |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.4M | 185.4M |
| IPO Year | 1996 | 2014 |
| Metric | ASUR | ELTX |
|---|---|---|
| Price | $8.79 | $14.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $14.33 | ★ $18.00 |
| AVG Volume (30 Days) | 83.9K | ★ 126.0K |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $88,952,000.00 | $2,301,000.00 |
| Revenue This Year | $16.33 | N/A |
| Revenue Next Year | $9.20 | N/A |
| P/E Ratio | $433.50 | ★ N/A |
| Revenue Growth | ★ 63.39 | N/A |
| 52 Week Low | $6.80 | $7.37 |
| 52 Week High | $11.47 | $16.00 |
| Indicator | ASUR | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 67.60 |
| Support Level | $7.91 | $9.76 |
| Resistance Level | $8.91 | N/A |
| Average True Range (ATR) | 0.38 | 1.30 |
| MACD | -0.03 | 0.35 |
| Stochastic Oscillator | 17.36 | 79.67 |
Asure Software Inc is a provider of cloud-based Human Capital Management (HCM) software solutions delivered as Software-as-a-Service (SaaS) to businesses of all sizes. It facilitates small and mid-sized businesses (SMBs) to develop their Human Capital to get to the next level, stay compliant, and allocate their time, money, and technology toward growth. The company's HCM suite, named AsureHCM, includes cloud-based Payroll and Tax, HR, a Time and Attendance software. Its HR services range from HR projects to outsourcing payroll to HR consulting services. The firm sells its products majorly in the United States.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.